Dalia M.

Cancer Doctor in Washington, D.C. Sherlock loving Hematologist Oncologist. Data science and informatics lover. Reality 🧜‍♀️ 🎹 🎤⚽️

[Eric Topol @EricTopol]

We've written about AI-induced physician deskilling that has already surfaced
https://t.co/iMy6zyWnhZ @tberzin
AI-induced never-skilling among newly trained doctors, while not yet proven, is a serious concern that needs to be addressed @NatureMedicine @nliulab
https://t.co/yov3YvsGti

[Dalia M. @DCCancerDoc]

@UMDRightNow #UMDlice
#shutDownUMDcampus

[Dalia M. @DCCancerDoc]

Exciting presentation at #ET24
Thank you @NaglaAKarimMD and the speakers

[Dr. Nagla Abdel Karim @NaglaAKarimMD]

⁦@DCCancerDoc⁩ chaired the session for Areas of Unmet Needs to be considered for future drug development in Oncology #ET24. Stay Tuned for next years’ exciting topics! ⁦@InovaCME⁩ ⁦@InovaSchar⁩ ⁦@InovaHealth⁩

[Dr. Nagla Abdel Karim @NaglaAKarimMD]

⁦@DCCancerDoc⁩ chaired the session for Areas of Unmet Needs to be considered for future drug development in Oncology #ET24. Stay Tuned for next years’ exciting topics! ⁦@InovaCME⁩ ⁦@InovaSchar⁩ ⁦@InovaHealth⁩

[Dr. Nagla Abdel Karim @NaglaAKarimMD]

⁦@MPishvaian⁩ How to improve accrual/Discover the clues to success of Phase I Programs #ET24 ⁦@InovaSchar⁩ ⁦@InovaHealth⁩ ⁦@InovaCME⁩

[Dr. Nagla Abdel Karim @NaglaAKarimMD]

⁦@AnwaarSaeed3⁩ presents Novel Agents Exploration in MRD Positive Colorectal Cancer Post Definitive Surgery and Chemotherapy. Excellent point of utilizing potentially effective novel agents in the adjuvant setting #ET24

[Dalia M. @DCCancerDoc]

Finally met papa Hem in person

Symposium for Evolving Therapies and Drug Development in Oncology
INOVA

@AaronGoodman33
@NaglaAKarimMD

[Dalia M. @DCCancerDoc]

Excellent talk on AML at 2024 Hematology Update Symposium by
Dr. Nassereddine

[Dalia M. @DCCancerDoc]

@SamahNd @Cancer_talks @GWCancer
Excellent talk on AML at 2024 Hematology Update Symposium by
Dr. Nassereddine

[David Steensma, MD @DavidSteensma]

@Dr_AmerZeidan Do your best work to prolong life and alleviate suffering, advocate tirelessly for your patients, have a life outside of medicine - and always remember that it is the patient's story that you were privileged to witness and play a role in, not your story.

[Dalia M. @DCCancerDoc]

✅✅✅

[Keith Siau @drkeithsiau]

How to write a paper by @AndrewMIbrahim

[Dalia M. @DCCancerDoc]

@Dr_AmerZeidan Always 😬😋

[Dalia M. @DCCancerDoc]

🇲🇦🇲🇦🇲🇦

[ESPN FC @ESPNFC]

MOROCCO TOPS GROUP F! 🇲🇦

THE FIRST AFRICAN TEAM TO WIN THEIR GROUP THIS CENTURY 👏

[صدقة جارية لسالم @salimsadaqa]

#سورة_الكهف
#يوم_الجمعة
اسقوا غِراس جُمعتكم بـ سورة الكهف
فإنها نورٌ بين الجُمعتين .. 🤍

[Dalia M. @DCCancerDoc]

This

[Garth Nicholas @Garth_Nicholas1]

Over time I’ve tweeted a lot about evidence-based medicine. But oncologists are often in situations with little or no evidence to guide them.

In these situations we go to “first principles”. But what are the first principles? Here’s a thread outlining those I think are key.

[Dalia M. @DCCancerDoc]

Small Cell Lung Cancer SCLC SOC discussed by Dr. @StephenVLiu at #DCLung22 with highlights including promising agents. Scratching the surface still with biomarkers

[Dalia M. @DCCancerDoc]

@Cancer_talks @StephenVLiu #DCLung22 excellent presentation Dr. Haroun at the D.C. Lung Cancer Conference 2022

[Stephen V Liu, MD @StephenVLiu]

Dr. Faysal Haroun @Cancer_talks discusses the different 1L chemo-free IO options in NSCLC. Despite crossover, clear OS benefit makes 1L IO the clear SOC but different delivery options. Dual checkpoint blockade with impressive long term OS but in need of biomarkers. #DCLung22

[Dalia M. @DCCancerDoc]

#DCLung22
@StephenVLiu

[Stephen V Liu, MD @StephenVLiu]

Antibody drug conjugates increasingly relevant for NSCLC as discussed by Dr. @benlevylungdoc at #DCLung22 with highlights including trastuzumab deruxtecan (T-DXd) in #HER2 mutant NSCLC (dose is 5.4 mg/kg) and patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC. #LCSM

[Dalia M. @DCCancerDoc]

#DCLung22

[Stephen V Liu, MD @StephenVLiu]

Update on #ROS1 NSCLC by Dr. @JessicaJLinMD at #DCLung22 including latest data on repotrectinib from #ENA2022. Promising activity with novel agents including against ROS1 G2032R especially NVL-520 with compelling (early) efficacy and safety data, first presented a few days ago!

[Dalia M. @DCCancerDoc]

Screening saves lives #DCLung22

[Stephen V Liu, MD @StephenVLiu]

Dr. @BrendonStilesMD explains why all of us need to be involved with lung cancer screening, addressing some of the common misconceptions and stressing that screening saves lives. #DCLung22 #LCSM